Skip to content
Peptides Networkby Compounded Health
Menu

Article

BPC-157 and TB-500 in Sport: Anti-Doping Status, FDA Review and Evidence

Both are prohibited at all times under the 2026 WADA List, in different classes, and neither has published human evidence for injury recovery

3 min read Evidence checked October 18, 2026 Key takeaways 7 sources

In this article

Key takeaways

BPC-157 (class S0, Specified) and TB-500 (class S2, non-Specified) are both prohibited at all times under the 2026 WADA Prohibited List. Neither is an FDA-approved drug, and FDA's reviews for its July 2026 advisory meeting found almost no human data for either.

Evidence available
Regulatory documents
Confidence
High The classifications are read directly from the 2026 Prohibited List, and the evidence statements come from FDA's own briefing documents for its July 2026 advisory meeting.
Main limitation
The WADA List is revised every year; this page reflects the 2026 List, and evidence of benefit in people is too sparse to weigh.
Evidence checked See all 7 sources
AI-generated illustration: glass petri dishes on a dark laboratory bench in soft blue light, with faint molecules and a DNA helix. Conceptual artwork.
AI-generated illustration · conceptual artwork

U.S. regulatory status

  • BPC-157

    Not FDA-approved

    Not a component of any FDA-approved drug and no USP monograph (FDA briefing, July 2026); FDA proposed it not be added to the 503A Bulks List

    Source 3, verified

  • TB-500 (thymosin beta-4 fragment 17-23)

    Not FDA-approved

    Not an FDA-approved drug (Drugs@FDA search, 2026-10-18); FDA proposed it not be added to the 503A Bulks List (FDA briefing, July 2026)

    Source 4, verified

BPC-157 and TB-500 are both prohibited in sport at all times, in and out of competition, but they sit in different classes of the World Anti-Doping Agency’s list. Under the 2026 Prohibited List, in effect since January 1, 2026, BPC-157 falls under S0, non-approved substances, and every substance in S0 is a Specified Substance. TB-500 falls under S2 as a derivative of thymosin beta-4, and every substance in S2 is non-Specified 1. Neither is an FDA-approved drug. FDA’s reviews for its July 2026 advisory meeting found no published use of TB-500 in patients and no human pharmacokinetic data for BPC-157 3,4. The earlier version of this page placed TB-500 in S0 and called both substances non-Specified; both statements were wrong.

What the two substances are

BPC-157 is a chain of 15 amino acids, described as a fragment of a protein originally isolated from human gastric juice 3. TB-500 is a synthetic seven-amino-acid fragment, positions 17 to 23, of thymosin beta-4, a 43-amino-acid peptide. FDA notes that products sold as TB-500 have included different salts and derivatives under the same name 4. When TB-500 was nominated for compounding, the three studies cited in support were studies of thymosin beta-4, not of TB-500 4.

Where they sit on the 2026 WADA List

S0 covers any pharmacological substance that is not addressed elsewhere on the List and has no current approval by any government health authority for human therapeutic use, such as drugs still in development or approved only for veterinary use. The List names BPC-157 as an example 1. BPC-157 has been named in S0 since the 2022 List 2.

S2 covers peptide hormones, growth factors and related substances. Its section on growth factors lists “thymosin-β4 and its derivatives e.g. TB-500” 1.

“Specified” does not mean permitted or less serious. The List quotes the World Anti-Doping Code: Specified Substances “should not in any way be considered less important or less dangerous than other doping substances,” but are more likely to have been used for a purpose other than improving performance 1. WADA explains that an athlete may receive a reduced sanction for a Specified Substance if it can be shown that it was not used for doping, and that the athlete remains responsible for any substance found in their body 7. This page does not describe how any individual case is decided, and the List is revised every year.

What is known about effects in people

FDA reviewed both substances for its July 2026 advisory meeting, when it considered whether to add them to the list of bulk drug substances that pharmacies may use for compounding 5. For TB-500, FDA did not find any information in the medical literature in which it was given to patients for any disease or condition, including wound healing 4. For BPC-157, FDA found no human pharmacokinetic data after oral, injected, nasal or skin administration, and did not identify clinical studies in Crohn’s disease, celiac disease or tendonitis 3. Animal and cell studies of BPC-157 are numerous: 24 of the 25 articles submitted with its nomination described effects in such models 3. Results in animals do not establish that an athlete’s injury recovers faster.

FDA status

Neither substance is the active ingredient of an FDA-approved drug. For BPC-157, FDA states that there is no USP monograph and that it is not a component of any FDA-approved drug 3. FDA lists both among bulk drug substances for compounding that may present significant safety risks, citing a possible immune reaction to the peptide and a lack of human safety information 6. For its advisory committee meeting of July 23, 2026, FDA proposed that neither BPC-157 nor TB-500, in free-base or acetate form, be added to the 503A list of substances pharmacies may use for compounding 5. For what FDA has and has not decided since, see Peptide compounding in 2026.

Topics

  • BPC-157
  • TB-500
  • WADA
  • anti-doping
  • sports medicine

Sources

7 sources. Numbers in the text link to the entry they cite.

  1. 1.
    World Anti-Doping Code International Standard: Prohibited List 2026

    World Anti-Doping Agency. wada-ama.org. 2025.

    Other sourcewada-ama.orgChecked October 18, 2026

    Cited for: In effect 1 January 2026; S0 non-approved substances names BPC-157, all S0 substances Specified; S2.3 lists 'Thymosin-β4 and its derivatives e.g. TB-500', all S2 substances non-Specified; prohibited at all times; Code Article 4.2.2 quotation on Specified Substances

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)

  2. 2.
    World Anti-Doping Code International Standard: Prohibited List 2022

    World Anti-Doping Agency. wada-ama.org. 2021.

    Other sourcewada-ama.orgChecked October 18, 2026

    Cited for: First List naming BPC-157 in S0 (absent from the 2021 List)

    Back to text

  3. 3.
    FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), PCAC meeting July 23-24, 2026

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: 15 amino acids; pentadecapeptide fragment of BPC originally isolated from human gastric juice; no USP monograph and not a component of an FDA-approved drug; no human pharmacokinetic data after oral, SC, nasal or transdermal use; no clinical studies identified in Crohn's disease, celiac disease or tendonitis; 24 of 25 nominator articles nonclinical; balancing weighs against listing

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)

  4. 4.
    FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), PCAC meeting July 23-24, 2026

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: TB-500 a synthetic N-acetylated heptapeptide, residues 17-23 of 43-amino-acid thymosin β4; multiple salts and derivatives sold under the name; the three nominator references were studies of thymosin β4; no information found in which TB-500 was administered to patients; balancing weighs against listing

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)

  5. 5.
    July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document Introduction

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: FDA proposing that BPC-157 and TB-500, free base and acetate, NOT be included on the 503A Bulks List

    Back to text (a)Back to text (b)

  6. 6.
    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: BPC-157 and TB-500 (thymosin beta-4 fragment LKKTETQ) listed among substances previously in category 2 whose nominations were withdrawn; immunogenicity risk; no or limited human safety information

    Back to text

  7. 7.
    Prohibited List (WADA web page)

    World Anti-Doping Agency. wada-ama.org. 2026.

    Other sourcewada-ama.orgChecked October 18, 2026

    Cited for: Specified status means the athlete may receive a reduced sanction if it can be proven that the substance was not used for doping purposes; does not relieve strict liability

    Back to text

Next read

Follow Compounded Health InstagramFacebook

Back to Peptides Network Back to top